走进利拉鲁肽 更多 >>
继日本中央社会保险医疗委员会批准了Victoza®（利拉鲁肽）的定价之后，诺和诺德制药公司计划将尽快在当地市场推出这种产品。诺和诺德表示，Victoza®是首个在日本获准上市的GLP-1类药物，既可以单独用药，也可以作为辅助药物与磺脲类降糖药(SU)联用。
综述：各种GLP-1受体激动剂及DPP-4抑制剂的有效性及安全性
Objective: Provide a comprehensive overview of efficacy and safety data on incretin-based agents in the treatment of type 2 diabetes.
Data sources: A PubMed search was conducted for the years 2000–2009, using as keywords the names of glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide and liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, alogliptin,
and saxagliptin). World Diabetes Congress abstracts from 2008 to 2009 were also searched for clinical studies of these agents.
Study selection: The author included randomized controlled trials of incretin therapies that were published in English and enrolled ≥100 participants.
Data extraction: Data on the effects of incretins on glycemic control, weight,beta-cell function, blood pressure, lipid levels, safety, and tolerability were extracted and summarized.
Data synthesis: A total of 27 randomized controlled studies of incretin therapy were identified and included in the review. GLP-1 receptor agonists and DPP-4 inhibitors were evaluated at different points in the diabetes treatment spectrum, i.e.,
added to diet and exercise alone (monotherapy) or added to oral antihyperglycemic regimens (combination therapy).
Conclusion: In addition to decreasing glycemia in type 2 diabetes, incretin therapies may improve other important parameters, including beta-cell function, blood pressure, and lipid levels, with a low risk for hypoglycemia. A comparison of the study data differentiates the clinical profiles of the GLP-1 receptor agonists, which are associated with weight loss, and DPP-4 inhibitors, which are weight neutral, as well as the individual agents within each class.
Keywords: Type 2 diabetes, GLP-1 receptor agonists, DPP-4 inhibitors, liraglutide, exenatide LAR, sitagliptin, saxagliptin, alogliptin.
编辑: helen
以下网友留言只代表网友个人观点，不代表网站观点
